🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. SHP640

    Takeda

    Adenoviral Conjunctivitis

    phase 3 small molecule terminated

    2 trials

  2. SHP640

    Takeda

    Bacterial Conjunctivitis

    phase 3 small molecule completed

    1 trial

  3. SOTYKTU 6 mg film-coated tablets, Matching Placebo for Deucravacitinib, SOTYKTU 6 mg film-coated tablets, SOTYKTU 6 mg film-coated tablets, ZASOCITINIB, SOTYKTU 6 mg film-coated tablets, Matching Placebo for TAK-279

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  4. SPD422 (anagrelide hydrochloride)

    Takeda

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

  5. SPD465

    Takeda

    Attention-Deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    2 trials

  6. SPD476

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  7. SPD476 (1.2g)

    Takeda

    Diverticulitis

    phase 3 small molecule completed

    1 trial

  8. SPD476 (mesalazine)

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  9. SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  10. SPD476, MMX™ mesalazine, 1.2g extended release tablet

    Takeda

    Diverticulitis

    phase 3 small molecule completed

    1 trial

  11. SPD489

    Takeda

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  12. SPD489

    Takeda

    ADHD

    phase 3 small molecule terminated

    1 trial

  13. SPD489

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  14. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Binge Eating Disorder

    phase 3 small molecule completed

    2 trials

  15. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    2 trials

  16. SPD489 (Lisdexamfetamine dimesylate) + Antidepressant

    Takeda

    Major Depressive Disorder

    phase 3 small molecule terminated

    1 trial

  17. SPD489 40mg

    Takeda

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  18. SPD489 Low-Dose

    Takeda

    Negative Symptoms of Schizophrenia

    phase 3 small molecule terminated

    1 trial

  19. SPD489 low dose range (40mg, 80mg, and 100mg)

    Takeda

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  20. SPD503 (1 mg)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  21. SPD503 (Guanfacine hydrochloride)

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial

  22. SPD503 (Guanfacine hydrochloride) (2 mg)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  23. SPD503-AM

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial

  24. SYR-322-MET

    Takeda

    Clinical Pharmacology

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources